MetaCap

Radiopharm Theranostics Limited ADR (RADX)

NASDAQ: RADXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.6304-0.0678 (-9.71%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RADX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.64
52-week range
0.63 – 16.25
Day range
0.63 – 0.716
Volume / Avg
12.98K / 55.23K
Beta
—

52-week range

$0.63$16.25

RADX stock today

On Nov 20, RADX ended the session at $0.6304, shedding $0.0678 (9.71%), versus the S&P 500's 3.70% decline. Trading was light, with 12.98K shares changing hands, about 24% of the average daily volume. Shares are 96.1% below their 52-week high of $16.25, set on Dec 15, 2025 and 0.1% above the 52-week low of $0.63, near the bottom of the past year's range.

RADX is down 87.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 86.1%. Radiopharm Theranostics has posted a net loss over the last twelve months (EPS of -$3.64), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Radiopharm Theranostics

Company profile

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Riccardo Canevari
Headquarters
Carlton, VIC
Employees
14

Financial highlights

Full financials

In fiscal 2025, Radiopharm Theranostics generated $3.6 million in revenue, up 1114.3% from fiscal 2024, its 2nd consecutive year of revenue growth. Radiopharm Theranostics reported a net loss of $38.3 million, compared with a loss of $47.9 million a year earlier. Gross margin was 1.1% (down from 100.0%) and operating margin -1050.6%.

Radiopharm Theranostics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$3.63M$299.23K$292.36K
Growth+1114.27%+2.35%—
Net income$-38.34M$-47.95M$-34.61M
EPS (diluted)$-1.76$-12.41$-11.32

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$16.99+2595.11%

  • Strong buy 1
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.44High $30.01

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

RADX news

All RADX news

Radiopharm Theranostics peers

Health Care sector
RADX peer companies
CompanyPrice% ChgMarket capCompare
ASBPAspire-Lakewood Holdings Inc.7.13-5.44%$10.00Mvs RADX
CMMBChemomab Therapeutics Ltd. ADR1.19+4.39%$9.58Mvs RADX
BFRIBiofrontera Inc.0.53-7.02%$9.51Mvs RADX
AEONAEON Biopharma Inc. Class A0.123-7.59%$10.35Mvs RADX
GDTCCytoMed Therapeutics Limited0.755-2.33%$9.01Mvs RADX
CALCCalciMedica Inc.1.26+7.69%$8.69Mvs RADX
OPTHOptimi Health Corp.1.51-13.71%$8.65Mvs RADX
BIVIBioVie Inc. Class A0.80-12.07%$8.58Mvs RADX

Indexes, lists and sector

Radiopharm Theranostics stock FAQ

What is Radiopharm Theranostics's stock price today?

RADX last traded at $0.6304 as of Nov 20, 4:00 PM EST, down 9.71% on the day. Prices are delayed at least 15 minutes.

Who is Radiopharm Theranostics's CEO?

Mr. Riccardo Canevari is the chief executive officer of Radiopharm Theranostics Limited ADR, which has about 14 employees.

What is the RADX 52-week high?

The 52-week high for RADX is $16.25 and the 52-week low is $0.63. The stock is currently 96.1% below its high.

Compare RADX